View in EDS

Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study.

Saved in:
Bibliographic Details
Title: Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study.
Authors: Noureddin M; Houston Methodist Hospital, Houston, TX, USA; Houston Research Institute, Houston, TX, USA. Electronic address: mnoureddin@houstonmethodist.org., Harrison SA; Pinnacle Clinical Research, San Antonio, TX, USA., Loomba R; MASLD Research Center, Division of Gastroenterology and Hepatology, University of California at San Diego, La Jolla, California, USA., Alkhouri N; Summit Clinical Research, San Antonio, TX, USA; Clinical Research Institute of Ohio, Westlake, OH, USA., Chalasani N; Indiana University School of Medicine, Indianapolis, IN, USA., Sheikh MY; Fresno Clinical Research Center, Fresno, CA, USA., Tomah S; Altimmune, Gaithersburg, MD, USA., Gutierrez JA; Altimmune, Gaithersburg, MD, USA; Scripps Clinic, La Jolla, CA, USA., Urbina S; Altimmune, Gaithersburg, MD, USA., Suschak JJ; Altimmune, Gaithersburg, MD, USA., Brown R; Altimmune, Gaithersburg, MD, USA., Odili O; Altimmune, Gaithersburg, MD, USA., Yang J; Altimmune, Gaithersburg, MD, USA., Keeton S; Altimmune, Gaithersburg, MD, USA., Neff G; Covenant Metabolic Specialists, Fort Myers, FL, USA., Mena E; California Liver Research Institute, Pasadena, CA, USA., Roberts MS; Altimmune, Gaithersburg, MD, USA., Browne SK; Altimmune, Gaithersburg, MD, USA., Harris MS; Altimmune, Gaithersburg, MD, USA.
Source: Lancet (London, England) [Lancet] 2025 Dec 06; Vol. 406 (10520), pp. 2644-2655. Date of Electronic Publication: 2025 Nov 11.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Multicenter Study
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41237796
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Noureddin+M%22">Noureddin M</searchLink>; Houston Methodist Hospital, Houston, TX, USA; Houston Research Institute, Houston, TX, USA. Electronic address: mnoureddin@houstonmethodist.org.<br /><searchLink fieldCode="AU" term="%22Harrison+SA%22">Harrison SA</searchLink>; Pinnacle Clinical Research, San Antonio, TX, USA.<br /><searchLink fieldCode="AU" term="%22Loomba+R%22">Loomba R</searchLink>; MASLD Research Center, Division of Gastroenterology and Hepatology, University of California at San Diego, La Jolla, California, USA.<br /><searchLink fieldCode="AU" term="%22Alkhouri+N%22">Alkhouri N</searchLink>; Summit Clinical Research, San Antonio, TX, USA; Clinical Research Institute of Ohio, Westlake, OH, USA.<br /><searchLink fieldCode="AU" term="%22Chalasani+N%22">Chalasani N</searchLink>; Indiana University School of Medicine, Indianapolis, IN, USA.<br /><searchLink fieldCode="AU" term="%22Sheikh+MY%22">Sheikh MY</searchLink>; Fresno Clinical Research Center, Fresno, CA, USA.<br /><searchLink fieldCode="AU" term="%22Tomah+S%22">Tomah S</searchLink>; Altimmune, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Gutierrez+JA%22">Gutierrez JA</searchLink>; Altimmune, Gaithersburg, MD, USA; Scripps Clinic, La Jolla, CA, USA.<br /><searchLink fieldCode="AU" term="%22Urbina+S%22">Urbina S</searchLink>; Altimmune, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Suschak+JJ%22">Suschak JJ</searchLink>; Altimmune, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Brown+R%22">Brown R</searchLink>; Altimmune, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Odili+O%22">Odili O</searchLink>; Altimmune, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Yang+J%22">Yang J</searchLink>; Altimmune, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Keeton+S%22">Keeton S</searchLink>; Altimmune, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Neff+G%22">Neff G</searchLink>; Covenant Metabolic Specialists, Fort Myers, FL, USA.<br /><searchLink fieldCode="AU" term="%22Mena+E%22">Mena E</searchLink>; California Liver Research Institute, Pasadena, CA, USA.<br /><searchLink fieldCode="AU" term="%22Roberts+MS%22">Roberts MS</searchLink>; Altimmune, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Browne+SK%22">Browne SK</searchLink>; Altimmune, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Harris+MS%22">Harris MS</searchLink>; Altimmune, Gaithersburg, MD, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%222985213R%22">Lancet (London, England)</searchLink> [Lancet] 2025 Dec 06; Vol. 406 (10520), pp. 2644-2655. <i>Date of Electronic Publication: </i>2025 Nov 11.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>2985213R <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-547X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201406736%22">01406736 </searchLink><i>NLM ISO Abbreviation: </i>Lancet <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41237796
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S0140-6736(25)02114-2
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2644
    Titles:
      – TitleFull: Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Noureddin M
      – PersonEntity:
          Name:
            NameFull: Harrison SA
      – PersonEntity:
          Name:
            NameFull: Loomba R
      – PersonEntity:
          Name:
            NameFull: Alkhouri N
      – PersonEntity:
          Name:
            NameFull: Chalasani N
      – PersonEntity:
          Name:
            NameFull: Sheikh MY
      – PersonEntity:
          Name:
            NameFull: Tomah S
      – PersonEntity:
          Name:
            NameFull: Gutierrez JA
      – PersonEntity:
          Name:
            NameFull: Urbina S
      – PersonEntity:
          Name:
            NameFull: Suschak JJ
      – PersonEntity:
          Name:
            NameFull: Brown R
      – PersonEntity:
          Name:
            NameFull: Odili O
      – PersonEntity:
          Name:
            NameFull: Yang J
      – PersonEntity:
          Name:
            NameFull: Keeton S
      – PersonEntity:
          Name:
            NameFull: Neff G
      – PersonEntity:
          Name:
            NameFull: Mena E
      – PersonEntity:
          Name:
            NameFull: Roberts MS
      – PersonEntity:
          Name:
            NameFull: Browne SK
      – PersonEntity:
          Name:
            NameFull: Harris MS
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 06
              M: 12
              Text: 2025 Dec 06
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1474-547X
          Numbering:
            – Type: volume
              Value: 406
            – Type: issue
              Value: 10520
          Titles:
            – TitleFull: Lancet (London, England)
              Type: main
ResultId 1